Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Clinical trial NCT05377307 · RECRUITING

Trial details

NCT number: NCT05377307
Sponsor: Pell Bio-Med Technology Co., Ltd.
Status: RECRUITING
Study type: OBSERVATIONAL

Diffuse Large B Cell Lymphoma Large B-cell Lymphoma Primary Mediastinal Large B Cell Lymphoma Follicular Lymphoma Grade 3A Follicular Lymphoma Grade 3B

Start date: 2022-12-29
Primary completion: 2036-12-01
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.